Literature DB >> 25262637

A single nucleotide polymorphism in osteonectin 3' untranslated region regulates bone volume and is targeted by miR-433.

Neha S Dole1, Kristina Kapinas, Catherine B Kessler, Siu-Pok Yee, Douglas J Adams, Renata C Pereira, Anne M Delany.   

Abstract

Osteonectin/SPARC is one of the most abundant noncollagenous extracellular matrix proteins in bone, regulating collagen fiber assembly and promoting osteoblast differentiation. Osteonectin-null and haploinsufficient mice have low-turnover osteopenia, indicating that osteonectin contributes to normal bone formation. In male idiopathic osteoporosis patients, osteonectin 3' untranslated region (UTR) single-nucleotide polymorphism (SNP) haplotypes that differed only at SNP1599 (rs1054204) were previously associated with bone mass. Haplotype A (containing SNP1599G) was more frequent in severely affected patients, whereas haplotype B (containing SNP1599C) was more frequent in less affected patients and healthy controls. We hypothesized that SNP1599 contributes to variability in bone mass by modulating osteonectin levels. Osteonectin 3' UTR reporter constructs demonstrated that haplotype A has a repressive effect on gene expression compared with B. We found that SNP1599G contributed to an miR-433 binding site, and miR-433 inhibitor relieved repression of the haplotype A, but not B, 3' UTR reporter construct. We tested our hypothesis in vivo, using a knock-in approach to replace the mouse osteonectin 3' UTR with human haplotype A or B 3' UTR. Compared with haplotype A mice, bone osteonectin levels were higher in haplotype B mice. B mice displayed higher bone formation rate and gained more trabecular bone with age. When parathyroid hormone was administered intermittently, haplotype B mice gained more cortical bone area than A mice. Cultured marrow stromal cells from B mice deposited more mineralized matrix and had higher osteocalcin mRNA compared with A mice, demonstrating a cell-autonomous effect on differentiation. Altogether, SNP1599 differentially regulates osteonectin expression and contributes to variability in bone mass, by a mechanism that may involve differential targeting by miR-433. This work validates the findings of the previous candidate gene study, and it assigns a physiological function to a common osteonectin allele, providing support for its role in the complex trait of skeletal phenotype.
© 2014 American Society for Bone and Mineral Research. © 2014 American Society for Bone and Mineral Research.

Entities:  

Keywords:  GENETIC ANIMAL MODELS; HUMAN ASSOCIATION STUDIES; MOLECULAR PATHWAYS-REMODELING; NONCOLLAGENOUS PROTEINS; OSTEOPOROSIS

Mesh:

Substances:

Year:  2015        PMID: 25262637      PMCID: PMC4376624          DOI: 10.1002/jbmr.2378

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  46 in total

1.  Expression of the osteonectin gene potentially controlled by multiple cis- and trans-acting factors in cultured bone cells.

Authors:  P Dominguez; K Ibaraki; P G Robey; T E Hefferan; J D Termine; M F Young
Journal:  J Bone Miner Res       Date:  1991-10       Impact factor: 6.741

2.  miR-29 suppression of osteonectin in osteoblasts: regulation during differentiation and by canonical Wnt signaling.

Authors:  Kristina Kapinas; Catherine B Kessler; Anne M Delany
Journal:  J Cell Biochem       Date:  2009-09-01       Impact factor: 4.429

3.  Bone matrix osteonectin limits prostate cancer cell growth and survival.

Authors:  Kristina Kapinas; Katie M Lowther; Catherine B Kessler; Karissa Tilbury; Jay R Lieberman; Jennifer S Tirnauer; Paul Campagnola; Anne M Delany
Journal:  Matrix Biol       Date:  2012-04-16       Impact factor: 11.583

4.  Development and characterization of a conditionally immortalized human fetal osteoblastic cell line.

Authors:  S A Harris; R J Enger; B L Riggs; T C Spelsberg
Journal:  J Bone Miner Res       Date:  1995-02       Impact factor: 6.741

5.  Association between osteoprotegerin genetic variants and bone mineral density in Chinese women.

Authors:  Lianbing Shen; Yihua Qiu; Shunming Xing; Dechun Chen; Yazhong Zhu; Xiang He; Jinxin Wang; Jing Lai; Guohua Shi; Teng Liao; Junming Tan
Journal:  Int Immunopharmacol       Date:  2013-04-22       Impact factor: 4.932

6.  Accentuated osteoclastic response to parathyroid hormone undermines bone mass acquisition in osteonectin-null mice.

Authors:  Luciene Machado do Reis; Catherine B Kessler; Douglas J Adams; Joseph Lorenzo; Vanda Jorgetti; Anne M Delany
Journal:  Bone       Date:  2008-04-13       Impact factor: 4.398

7.  Diverse forms of stress result in changes in cellular levels of osteonectin/SPARC without altering mRNA levels in osteoligament cells.

Authors:  J J Sauk; K Norris; J M Kerr; M J Somerman; M F Young
Journal:  Calcif Tissue Int       Date:  1991-07       Impact factor: 4.333

8.  Infrared analysis of the mineral and matrix in bones of osteonectin-null mice and their wildtype controls.

Authors:  Adele L Boskey; David J Moore; Michael Amling; Ernesto Canalis; Anne M Delany
Journal:  J Bone Miner Res       Date:  2003-06       Impact factor: 6.741

9.  Osteonectin/SPARC polymorphisms in Caucasian men with idiopathic osteoporosis.

Authors:  A M Delany; D J McMahon; J S Powell; D A Greenberg; E S Kurland
Journal:  Osteoporos Int       Date:  2007-12-15       Impact factor: 4.507

10.  Polymorphisms in predicted miRNA binding sites and osteoporosis.

Authors:  Shu-Feng Lei; Christopher J Papasian; Hong-Wen Deng
Journal:  J Bone Miner Res       Date:  2011-01       Impact factor: 6.741

View more
  19 in total

Review 1.  MicroRNA variants as genetic determinants of bone mass.

Authors:  Neha S Dole; Anne M Delany
Journal:  Bone       Date:  2015-12-23       Impact factor: 4.398

Review 2.  Epigenetics of Skeletal Diseases.

Authors:  Alvaro Del Real; Leyre Riancho-Zarrabeitia; Laura López-Delgado; José A Riancho
Journal:  Curr Osteoporos Rep       Date:  2018-06       Impact factor: 5.096

Review 3.  Regulation of Bone Metabolism by microRNAs.

Authors:  Hanna Taipaleenmäki
Journal:  Curr Osteoporos Rep       Date:  2018-02       Impact factor: 5.096

Review 4.  MicroRNAs in bone diseases.

Authors:  L Gennari; S Bianciardi; D Merlotti
Journal:  Osteoporos Int       Date:  2016-11-30       Impact factor: 4.507

Review 5.  SPARC/osteonectin in mineralized tissue.

Authors:  Emilie M Rosset; Amy D Bradshaw
Journal:  Matrix Biol       Date:  2016-02-03       Impact factor: 11.583

6.  Recessive osteogenesis imperfecta caused by missense mutations in SPARC.

Authors:  Roberto Mendoza-Londono; Somayyeh Fahiminiya; Jacek Majewski; Martine Tétreault; Javad Nadaf; Peter Kannu; Etienne Sochett; Andrew Howard; Jennifer Stimec; Lucie Dupuis; Paul Roschger; Klaus Klaushofer; Telma Palomo; Jean Ouellet; Hadil Al-Jallad; John S Mort; Pierre Moffatt; Sergei Boudko; Hans-Peter Bächinger; Frank Rauch
Journal:  Am J Hum Genet       Date:  2015-05-28       Impact factor: 11.025

7.  SPARC gene variants predict clinical outcome in locally advanced and metastatic pancreatic cancer patients.

Authors:  Cristina Arqueros; Juliana Salazar; M J Arranz; Ana Sebio; Josefina Mora; Ivana Sullivan; María Tobeña; Marta Martín-Richard; Agustí Barnadas; Montserrat Baiget; David Páez
Journal:  Med Oncol       Date:  2017-07-07       Impact factor: 3.064

8.  Species-specific sensitivity to TGFβ signaling and changes to the Mmp13 promoter underlie avian jaw development and evolution.

Authors:  Spenser S Smith; Daniel Chu; Tiange Qu; Jessye A Aggleton; Richard A Schneider
Journal:  Elife       Date:  2022-06-06       Impact factor: 8.713

Review 9.  Skeletal biology: Where matrix meets mineral.

Authors:  Marian F Young
Journal:  Matrix Biol       Date:  2016-04-27       Impact factor: 11.583

Review 10.  Intrinsically disordered proteins and biomineralization.

Authors:  Adele L Boskey; Eduardo Villarreal-Ramirez
Journal:  Matrix Biol       Date:  2016-01-22       Impact factor: 11.583

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.